C urrent guidelines recommend dual antiplatelet therapy (DAPT) for at least 6 months (European Securities Committee)
Stent Thrombosis and DAPT Interruption
important. In a large registry study of patients receiving CoCr-EES, discontinuation of DAPT before 30 days was associated with an increased rate of ST 13 ; this study did not, however, examine the rates of ST as a function of DAPT discontinuation in circumscribed risk periods after 30 days. We therefore analyzed the relationship between ST and DAPT use through 2 years in a large, pooled sample of patients from the CoCr-EES Xience V family of clinical studies.
Methods

Patient Sample
The databases from 3 randomized trials and 4 registries in which 13 259 total patients received Xience V CoCr-EES (Abbott Vascular, Santa Clara, CA) were retrospectively pooled for analysis. Patients who received other DES are not included in the present analysis. The designs of these studies have been previously reported [14] [15] [16] [17] [18] [19] [20] and are summarized in Table 1 . We excluded 2040 patients (15.4%) because of incomplete DAPT data about DAPT usage (start date and interruption date), leaving 11 219 patients (84.6%) for the current analysis. All studies were approved by an institutional review committee, and subjects gave informed consent for use of their study data.
DAPT Usage and Interruption
At least 6 months of clopidogrel and 1 year or indefinite use of aspirin was required by protocol in the 3 randomized trials. [14] [15] [16] DAPT usage was recommended per standard of care in the 4 single-arm registry studies (Table 1) . [17] [18] [19] In all the studies, detailed DAPT usage data were recorded, including all medication start and stop dates. DAPT was considered to be interrupted if aspirin or a thienopyridine was not taken for at least 24 hours during the 2-year follow-up period for any reason. Permanent DAPT discontinuation was considered if DAPT was never resumed after discontinuation or never resumed before a ST event (if a ST occurred after DAPT discontinuation). The relationship between DAPT discontinuation and ST was examined according to whether the DAPT discontinuation was either temporary (the occurrence of DAPT interruption) versus on a permanent basis (permanent DAPT discontinuation). Two patients had multiple ST events; only the first was included in the present analysis.
End Points and Definitions
Definite and probable ST according to the Academic Research Consortium definition 21 were adjudicated in each study by an independent clinical event committee blinded to the baseline clinical findings (and stent assignment in the 3 randomized trials). DAPT discontinuation and ST rates were reported for the following commonly described time intervals after stent implantation: 0 to 30 days, 30 to 90 days, 90 to 180 days, 180 to 365 days, and 365 to 730 days. DAPT usage status at the time of ST presentation was also determined.
Statistical Analysis
Continuous variables are summarized as means±SD and were compared by t test. Categorical outcomes were compared by χ 2 or Fisher exact test. Survival curves for time-to-event variables were constructed using all available follow-up data, with event rates expressed as Kaplan-Meier estimates. Stepwise logistic regression was performed to determine the independent correlates of definite/probable ST, with variables entered into the model at the 0.20-significance level and removed at the 0.05 level (from the Wald χ 2 statistic). Variables were eligible for inclusion in the multivariable model-building process if the variable was present in 90% of the subjects, if highly correlated with another variable (r>0.5; P<0.05), and if had the higher level of significance. Variables entered into the 2-year multivariable logistic model were age, current tobacco use, angina Canadian Cardiovascular Society III or IV, previous cardiac intervention, diabetes mellitus requiring medication (insulin or oral medication), target lesion length, previous myocardial infarction, American College of Cardiology/ American Heart Association lesion classification, number of stents implanted, and total length of all stents. All P values are 2-sided, and P<0.05 was considered statistically significant. To further identify the effect of the timing of permanent DAPT discontinuation on the occurrence of ST within specific time periods of interest, a propensity score for DAPT discontinuation was performed for each of the following intervals: at any time, between 0 and 30 days, between 30 and 90 days, between 90 and 180 days, between 180 and 365 days, and >365 days. A Cox regression analysis was performed for each of these periods adjusted for the propensity score and DAPT usage as a time-dependent variable. Covariate variables in the propensity score were age, sex, diabetes mellitus, smoking status, hypertension, hypercholesterolemia, previous myocardial infarction, previous coronary artery bypass graft, Canadian cardiovascular class 3/4, lesion length, in-stent restenosis lesion, type B2/C lesion, bifurcation lesion, total stent length implanted, renal insufficiency, left ventricular ejection fraction, number of diseased vessels, lesion calcification, percent diameter stenosis, reference vessel diameter, number of treated vessels, coronary artery location, and baseline thrombolysis in myocardial infarction flow. All analyses were performed with SAS, version 9.2.
Results
Patients, Baseline Characteristics, and DAPT Interruption
A total of 11 219 patients undergoing CoCr-EES implantation in 14 963 lesions were included in the current analysis; 2-year follow-up was completed in 10 580 patients (94.3%). Baseline clinical, angiographic, and procedural characteristics of the study sample with complete DAPT data and the 2040 excluded patients without complete DAPT data are shown and compared in Table I in the Data Supplement. Antiplatelet usage throughout the 2 years for the study sample is shown in Table 2 . DAPT was interrupted at least once during the 2-year follow-up in 4080 patients (36.4%), whereas 7139 patients (63.6%) never discontinued DAPT (Table 3) . Cumulative rates of DAPT interruption are shown in Figure I in the Data Supplement.
WHAT IS KNOWN
• Stent thrombosis after second-generation drug-eluting stent implantation is rare but is still associated with high rates of death and myocardial infarction.
• Second-generation cobalt chromium everolimuseluting stents have been shown to be associated with a lower rates of stent thrombosis compared with bare metal stents or first-generation drug-eluting stents.
WHAT THE STUDY ADDS
• The majority of stent thrombosis events after cobalt chromium everolimus-eluting stent implantation occurred within the first 30 days after stent implantation while patients were still taking dual antiplatelet therapy.
• Dual antiplatelet therapy discontinuation before 30 days after cobalt chromium everolimus-eluting stent implantation was strongly associated with stent thrombosis, whereas dual antiplatelet therapy discontinuation beyond 90 days appeared safe. Stent Thrombosis and DAPT Interruption
ST According to DAPT Interruption
Among the total cohort, 85 definite/probable ST events (0.75%) occurred in 83 patients during 2 years ( Figure 1A) , with 41 events (48.2% of the total) occurring within 30 days ( Figure 1B ). Among the 85 ST events, 45 (52.9%) occurred in patients who never interrupted DAPT during the 2-year follow-up period, whereas 40 (47.1%) occurred in patients in whom DAPT was interrupted at some point during follow-up. Among those 40 events, 23 ST events occurred while patients were on-DAPT (actively taking DAPT at the time of the event), whereas 17 ST events occurred while patients were off-DAPT. Thus, 68 (80.0%) of the 85 total ST events occurred on-DAPT, whereas 17 (20.0%) ST events occurred off-DAPT. Among the 17 ST episodes that occurred off DAPT, the type of DAPT that was interrupted at the time of the ST event was aspirin only in 6 patients, a thienopyridine only in 6 patients, and both aspirin and a thienopyridine in 5 patients. Figure II in the Data Supplement illustrates the occurrence of ST in relation to DAPT usage over time. There was no significant difference in the ST rate in patients with (n=11 219) versus without (n=2040) complete DAPT data (0.8% versus 0.6% respectively, P=0.39). Among the 83 patients with ST, 58 patients (69.9%) never interrupted DAPT before the occurrence of ST, whereas DAPT was interrupted in 25 patients (30.1%) before the occurrence of ST. The rate of ST in patients who never interrupted DAPT compared with those who interrupted DAPT sometime during the 2-year follow-up was not significantly different (0.83% versus 0.63%, respectively; P=0.27). Of the 25 patients who interrupted DAPT, 9 and 16 were on-DAPT and off-DAPT at the time of the ST event. Moreover, as shown in Figure 3A and 3B, among patients in whom ST occurred, the times from CoCr-EES implantation to ST were paradoxically shorter in those patients in whom DAPT was never discontinued at any time (or until only after the ST) compared with those with earlier DAPT interruption before the ST.
Timing of ST According to DAPT Interruption
Relationship Between the Timing of Permanent DAPT Discontinuation and ST
Compared with patients in whom DAPT was never discontinued (or was only discontinued after a ST event), the frequency of ST in patients who permanently discontinued DAPT was strongly dependent on the timing of its discontinuation relative to CoCr-EES implantation (Figure 4) . DAPT discontinuation within the first 30 days after Figure 5 ).
Correlates of ST
Discussion
The current report, drawn from 11 219 patients undergoing percutaneous coronary intervention, is the largest study to date to evaluate the frequency and correlates of ST after CoCr-EES, especially as regards the effect of DAPT discontinuation. The main results of this study are as follows: (1) DAPT discontinuation was frequent, with 20.0% and 36.4% of patients having interrupted DAPT within 1 and 2 years of stent implantation; (2) the 2-year ST rate was low with the use of CoCr-EES (0.74%), with ≈50% of the events occurring within the first 30 days; (3) most episodes of ST with CoCr-EES occurred in patients on-DAPT and in those in whom DAPT had not been interrupted before ST; (4) compared with patients without DAPT discontinuation, permanent DAPT discontinuation within 30 days after CoCr-EES implantation was a strong correlate of subsequent ST; permanent DAPT discontinuation between 30 and 90 days after CoCr-EES implantation was also significantly associated with ST, although these data are less certain given the few events in this period; and permanent DAPT discontinuation beyond 90 days was not associated with subsequent ST. These findings question whether current DAPT guidelines recommending a minimum of 6 months or 1 year of DAPT, which were established during the era of first generation DES, are relevant to CoCr-EES.
Previous studies attempted to evaluate the effect of DAPT discontinuation on the occurrence of ST with CoCr-EES. 11, 13, 18, 22 Krucoff et al 18 demonstrated the absence of ST with DAPT interruption beyond 6 months after CoCr-EES implantation from a postmarket surveillance study of 5054 real-world patients. Kedhi et al 16, 22, 23 reported from a pooled analysis of 4 randomized trials that DAPT discontinuation beyond 6 months after CoCr-EES implantation may be safe. Valgimigli et al 11 recently reported from a multicenter randomized controlled trial in 2013 patients treated with either bare-metal stents or first-or second-generation DES that compared with 6 months of DAPT, 24 months of DAPT had no short-or long-term ischemic benefits, but was associated with significant increases in bleeding. However, none of those studies examined the specific timing of DAPT discontinuation, especially before 6 months. The present large-scale study thus confirms and extends these findings by demonstrating that even permanent DAPT discontinuation beyond 3 months after CoCr-EES implantation was not associated with a higher rate of ST when compared with patients without DAPT discontinuation during 2-year follow-up.
Importantly, the ST rate in patients interrupting DAPT was similar to that of patients who never interrupted DAPT. Values are presented as n/N (%) and represent the usage rates at exact specific times, with no windows. DAPT indicates dual antiplatelet therapy (both aspirin and a thienopyridine). Strikingly, 99.4% of 4080 patients who discontinued DAPT ≥1× times during the 2-year follow-up period did not experience ST. The low rate of ST (0.74%) throughout the 2-year follow-up period in this large experience including real-world patients is also of note, reinforcing the low rate of ST with CoCr-EES. 8, 9 The combination of thin struts, the thromboresistant durable fluorinated copolymer, and a relatively low dose of everolimus may contribute to the low ST rate observed with CoCr EES. Nonetheless, the first 30 days remain a period of increased risk for ST, even with CoCr-EES, reinforcing the need for meticulous stent implantation technique and a role for more potent ADP-receptor inhibition during this period in highrisk patients, such as those with acute coronary syndromes. 23, 24 Importantly, the vast majority (80%) of STs occurred while patients were on-DAPT, and 70% of patients had never discontinued DAPT for even 1 day before the ST event. In addition, the time to the occurrence of ST after CoCr-EES implantation was shorter among patients who never stopped DAPT before ST compared with those in whom ST developed after stopping DAPT. These observations suggest that variables other The first patient presented with a definite ST on day 3 postprocedure and had a recurrence on day 12. He was on DAPT for both events and never discontinued DAPT before these 2 events. The second patient experienced his first ST on day 7 and the second on day 132, being on DAPT for the entire 2 years. Stent Thrombosis and DAPT Interruption than DAPT interruption are responsible for the majority of ST among CoCr-EES-treated patients. Risk factors, such as diabetes mellitus, total length of stent implanted, acute coronary syndromes, renal insufficiency, and suboptimal stent implantation (eg, stent underexpansion and edge dissections), are known risk factors for ST [25] [26] [27] and may be more important than DAPT interruption in the pathogenesis of ST after CoCr-EES, at least after 3 months.
Naidu et al 13 previously identified DAPT interruption within 30 days as a correlate of ST within 1 year after CoCr-EES. In this study, after adjusting for differences in baseline characteristics affecting the propensity for DAPT discontinuation within each risk period, the odds of developing ST after permanent DAPT discontinuation before 1 month and between 1 and 3 months were, respectively, 27-fold and 9-fold higher than in patients with no permanent DAPT discontinuation. That being said, although permanent discontinuation inside 1 month was clearly associated with an increased risk of ST, the low number of events between 1 and 3 months precludes any definitive conclusion for this time period. Among patients who discontinued DAPT permanently between 1 and 3 months, only 2 STs occurred, both between 1 and 2 months. Had 1 less ST occurred in this period after premature DAPT discontinuation, the relationship between DAPT discontinuation and ST between 1 and 3 months would not have been significant. Thus, despite the size of our study, additional large-scale registries or randomized trials are needed to determine whether DAPT discontinuation between 1 and 3 months is safe after CoCr-EES. Interaction between patient factors (diabetes mellitus, renal insufficiency, acute coronary syndrome presentation, etc.) and lesion characteristics (total lesion length stented, severe calcification, etc.) and timing of DAPT discontinuation may also be especially important during this period. Conversely, cessation of DAPT beyond 3 months after CoCr-EES placement was not associated with an increased risk of ST. DAPT discontinuation at 3 months may even result in improved clinical outcomes from reduced major bleeding. Comparisons are between permanent discontinuation vs no permanent discontinuation (which includes no discontinuation at any time or temporary interruption). Analyses are unadjusted for differences in baseline variables. CI indicates confidence interval; and HR, hazard ratio. *Signifies or until after a ST event. Stent Thrombosis and DAPT Interruption Although several studies have suggested that a short DAPT regimen after DES is safe and may reduce bleeding, 11, 22, [28] [29] [30] [31] [32] [33] [34] the recent large-scale DAPT trial, comparing 30-month versus 12-month DAPT, demonstrated that prolonging DAPT after DES placement may reduce the rates of very late ST and major cardiovascular adverse events, although at the cost of increased major bleeding. 35 Numerous DES types were used in this study, however, and among patients receiving EES, only a small reduction in very late ST was present with prolonged DAPT, with no difference in major cardiovascular adverse events. Our present study is the largest to date to explore the effect of different durations of DAPT discontinuation after EES, with more patients (11 219 versus 4703) and ST events (83 versus 22) than in the DAPT trial, respectively. Although not randomized, our results thus add important and complementary information to the findings from the DAPT study. Finally, in randomized trials, prolonged DAPT has been associated with increased all-cause mortality because of greater noncardiovascular mortality, not offset by reduced cardiovascular mortality, reinforcing the need for an individualized risk-based approach to DAPT duration. [36] [37] [38] Collectively, these data suggest that a shorter DAPT duration (3-6 months) after EES may be preferred in patients without excessive ongoing ischemic risk.
Limitations
Although the Xience V studies in the present report were run by the sponsor in similar fashion, the patient cohorts and protocols varied somewhat and were conducted over the course of several years. Complete DAPT usage data were missing from 15.4% of patients enrolled in the 7 Xience V studies included in the present report, who were thus excluded from the analysis. As the baseline characteristics of the patients excluded because incomplete DAPT data were slightly different from that of the study cohort, we cannot rule out some degree of selection bias. In addition, although the present report is the first such analysis to adjust for differences in measured variables between patients in individual temporal risk periods, we cannot control for unmeasured confounders and thus cannot prove causality between DAPT discontinuation and ST. Although DAPT usage data were collected in a prospective manner at each followup visit, DAPT interruption assessment is intrinsically subject to retrospective ascertainment bias. Clinical circumstances and reasons for discontinuing DAPT were not systematically Values are presented as mean±SD or as n/N (%). Each denominator reflects the number of patients with complete data and follow-up for that variable. ACC/AHA indicates American College of Cardiology/American Heart Association; CABG, coronary artery bypass graft; MI, myocardial infarction; NSTEMI, non-ST-segment-elevation myocardial infarction; PCI, percutaneous coronary intervention; ST, stent thrombosis; and STEMI, ST-segment-elevation myocardial infarction. 29 The present analysis, although relevant to clinical decision-making about intervals for which DAPT is commonly prescribed, does not take into account the per-day risks of ST. Because the high-risk intervals for ST after DAPT discontinuation were also shorter in duration than the lower-risk intervals (eg, 30-90 days versus 365-730 days), the present results would likely have been more strongly evident in a time-based analysis. Although the largest study to date of its type, the relatively modest number of ST events precludes meaningful subgroup analysis, such as whether 1 month of DAPT may be sufficient for patients at low risk of ST or whether 6 months of DAPT (or longer) would be beneficial in higher risk patients (such as those presenting with an acute coronary syndrome). Similarly, there were not enough ST events to examine the implications of aspirin-only versus thienopyridine-only versus dual agent discontinuation on the risk of ST after Co-Cr-EES, although a recent large-scale study suggests that ST may be more related to platelet reactivity to clopidogrel than aspirin. 30 Several meta-analyses have reported that CoCr-EES have lower ST rates than other second-generation DES. 8, 9 The findings in the present report relating the timing of DAPT discontinuation to subsequent ST thus cannot be generalized to other DES. Finally, we defined DAPT interruption as medication nonuse for ≥24 hours, consistent with previous studies. 13 Although the proportion of ST events occurring on-versus off-DAPT would have varied slightly had we used a more prolonged duration to define DAPT interruption, as seen in Figure 3C , there were numerous cases in which such shortterm DAPT interruption may be related to ST.
Conclusions
In the present patient-level pooled analysis of 11 219 patients, ST occurred infrequently within 2 years after percutaneous coronary intervention with CoCr-EES. Most episodes of ST occurred in patients in whom DAPT was never discontinued (with the first 30 days being the greatest risk period), and the rate of ST in patients interrupting DAPT at any point was similar to that of patients who never interrupted DAPT throughout the 2-year follow-up period. Nonetheless, a relationship was observed between the timing of first DAPT discontinuation after CoCr-EES and ST. Specifically, DAPT discontinuation within 1 month of CoCr-EES implantation was strongly related to the subsequent development of ST, whereas permanent DAPT discontinuation beyond 3 months was not. Whether DAPT discontinuation between 1 and 3 months is safe in selected subsets of patients and lesions requires additional study. Large-scale, randomized trials of early DAPT discontinuation, especially after use of new generation P2Y 12 inhibitors, are required to definitively determine the safety and optimal timing of DAPT discontinuation in patients receiving CoCr-EES and other second-generation DES. The results of this study may be used to inform such a trial. Pending such data, the present results do provide some level of reassurance of safety for patients in whom DAPT must be or has been prematurely discontinued beyond 3 months after CoCr-EES implantation.
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